Major Strengths of the University of Rochester Wellstone MDCRC are: 10 years of experience in operating our current Wellstone Center;a large group of highly motivated patients with myotonic dystrophy (DM1) eager to support translational research and participate in clinical studies;enthusiastic investigators with longstanding expertise in clinical studies;collaborators sharing our urgent commitment to identify and validate reliable endpoints and biomarkers to prepare for treatment trials in DM1;and a nurturing environment that includes a NIH CTSI network and support from major stakeholders in the DM1 community. These assets will allow a network of neuromuscular clinical trialists to become trial ready and permit further exploration of RNA toxicity (spliceopathy) as a disease pathomechanism and biomarker. Our renewal Wellstone Center will support 2 scientific projects and 1 scientific resources core and seeks to validate promising clinical endpoint measures and skeletal muscle splicing alterations identified in our current Wellstone study. Project 1 in our renewal includes a multicenter validation study to confirm the usefulness of promising endpoint measures and will evaluate feasibility and reliability of small needle muscle biopsy splicing assays as a useful biomarker. A cohort of 100 DM1 patients will undergo identical clinical evaluations at 0 and 12 months to answer these questions. A larger cohort of 400 DM1 patients will undergo clinical exams to assess disease severity and provide blood for DNA analysis of DMPK CTG repeat size and genetic variants at MBNL1 and other loci. Our current muscle biopsy data indicate CTG repeat size in tissue does not predict the severity of muscle weakness, suggesting that other genetic factors may influence DM1. Project 2 will examine therapeutic effects of antisense drugs on cardiac function in transgenic mouse models of DM. The Scientific Core contains the National Registry of DM Patients and Family Members and Repository. It supports Projects 1 and 2. The Training/Education Core trains 1 pre-doctoral and 1 post-doctoral fellow and will provide educational materials.

Public Health Relevance

The projects and cores of our MDCRC prepare us for promising treatment trials of new therapies for DM1. The studies proposed for patients will help identify the most appropriate measures to evaluate therapy and detect therapeutic targets. The effects of new therapeutic agents on cardiac aspects of DM1 will be examined in animal models.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54NS048843-11
Application #
8585340
Study Section
Special Emphasis Panel (ZNS1-SRB-S (57))
Program Officer
Porter, John D
Project Start
2003-09-30
Project End
2018-08-31
Budget Start
2013-09-15
Budget End
2014-08-31
Support Year
11
Fiscal Year
2013
Total Cost
$1,467,548
Indirect Cost
$501,885
Name
University of Rochester
Department
Neurology
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Johnson, Nicholas E; Ekstrom, Anne-Berit; Campbell, Craig et al. (2016) Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy. Dev Med Child Neurol 58:698-705
Slean, Meghan M; Panigrahi, Gagan B; Castel, Arturo López et al. (2016) Absence of MutSβ leads to the formation of slipped-DNA for CTG/CAG contractions at primate replication forks. DNA Repair (Amst) 42:107-18
Fitzgerald, Bryan P; Conn, Kelly M; Smith, Joanne et al. (2016) Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy. J Neurol 263:2528-2537
Heatwole, Chad; Bode, Rita; Johnson, Nicholas E et al. (2016) Myotonic dystrophy health index: Correlations with clinical tests and patient function. Muscle Nerve 53:183-90
Gloss, David; Moxley 3rd, Richard T; Ashwal, Stephen et al. (2016) Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86:465-72
Heatwole, Chad; Johnson, Nicholas; Bode, Rita et al. (2015) Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2). Neurology 85:2136-46
Yadava, Ramesh S; Foff, Erin P; Yu, Qing et al. (2015) TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy. Hum Mol Genet 24:2035-48
Pandey, Sanjay K; Wheeler, Thurman M; Justice, Samantha L et al. (2015) Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J Pharmacol Exp Ther 355:329-40
Wojtkowiak-Szlachcic, Agnieszka; Taylor, Katarzyna; Stepniak-Konieczna, Ewa et al. (2015) Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. Nucleic Acids Res 43:3318-31
Smith, Amanda E; McMullen, Kara; Jensen, Mark P et al. (2014) Symptom burden in persons with myotonic and facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil 93:387-95

Showing the most recent 10 out of 74 publications